Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127339001 | 12733900 | 1 | I | 20151008 | 20151221 | 20160912 | 20160912 | EXP | JP-ROCHE-1691280 | ROCHE | 7.00 | DEC | M | Y | 77.00000 | KG | 20160912 | MD | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127339001 | 12733900 | 1 | PS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous drip | MOST RECENT DOSE: 12/NOV/2015 | Y | 125085 | 15 | MG/KG | SOLUTION FOR INFUSION | Q3W | |||||
| 127339001 | 12733900 | 2 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous drip | Y | 125085 | 15 | MG/KG | SOLUTION FOR INFUSION | Q3W | ||||||
| 127339001 | 12733900 | 3 | SS | Erlotinib | ERLOTINIB | 1 | Oral | MOST RECENT DOSE: 12/NOV/2015 | Y | 53728 | 150 | MG | TABLET | QD | |||||
| 127339001 | 12733900 | 4 | SS | Erlotinib | ERLOTINIB | 1 | Oral | Y | 53728 | 150 | MG | TABLET | QD | ||||||
| 127339001 | 12733900 | 5 | C | OLMETEC | OLMESARTAN MEDOXOMIL | 1 | Oral | 0 | 40 | MG | TABLET | QD | |||||||
| 127339001 | 12733900 | 6 | C | ATELEC | CILNIDIPINE | 1 | Oral | 0 | 20 | MG | TABLET | QD | |||||||
| 127339001 | 12733900 | 7 | C | DERMOVATE | CLOBETASOL | 1 | Unknown | 0.05% SCALP LOTION | 0 | TID | |||||||||
| 127339001 | 12733900 | 8 | C | MINOCYCLINE HYDROCHLORIDE. | MINOCYCLINE HYDROCHLORIDE | 1 | Unknown | 0 | 50 | MG | TABLET | ||||||||
| 127339001 | 12733900 | 9 | C | MARZULENE S | GLUTAMINESODIUM GUALENATE | 1 | Unknown | 0 | 1.5 | G |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127339001 | 12733900 | 1 | Lung adenocarcinoma |
| 127339001 | 12733900 | 2 | Lung adenocarcinoma |
| 127339001 | 12733900 | 3 | Non-small cell lung cancer |
| 127339001 | 12733900 | 4 | Lung adenocarcinoma |
| 127339001 | 12733900 | 5 | Hypertension |
| 127339001 | 12733900 | 6 | Hypertension |
| 127339001 | 12733900 | 7 | Dermatitis acneiform |
| 127339001 | 12733900 | 8 | Dermatitis acneiform |
| 127339001 | 12733900 | 9 | Abdominal pain upper |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127339001 | 12733900 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127339001 | 12733900 | Alanine aminotransferase increased | |
| 127339001 | 12733900 | Aspartate aminotransferase increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127339001 | 12733900 | 1 | 20151001 | 0 | ||
| 127339001 | 12733900 | 2 | 20151126 | 0 | ||
| 127339001 | 12733900 | 3 | 20151001 | 0 | ||
| 127339001 | 12733900 | 4 | 20151127 | 0 | ||
| 127339001 | 12733900 | 5 | 20151001 | 0 | ||
| 127339001 | 12733900 | 6 | 20151001 | 0 |